Medical Ikkou Group Co.,Ltd. Q2 FY2026 earnings call

• Overall Consolidated Performance

  • 2nd quarter total consolidated revenue is 26.935 billion yen, 635 million yen above the initial plan. Total operating profit is 743 million yen, 157 million yen below the initial plan. Ordinary profit hit 880 million yen, roughly in line with plan. Interim net profit reached 666 million yen, 116 million yen above the initial plan, reaching 53.3% of the full-year net profit target of 1.25 billion yen.
  • Interim revenue and ordinary profit both reached all-time record highs for any first half in the company's history.

• M&A Activity

  • M&A is a core growth pillar of the company's mid-term management plan announced in April. In the reporting interim period, the company completed three M&A deals: two in the pharmaceutical wholesale segment and one in the healthcare segment. The addition of newly acquired subsidiaries is the primary driver of the segment's strong revenue growth this period.
  • The company plans to merge the two newly acquired pharmaceutical wholesale subsidiaries into Medical Ichiko in the second half of the fiscal year, to strengthen organizational structure and deliver integration synergies as early as possible.
  • As of the end of the interim period, the company's network has expanded to cover 1 capital, 1 district, 2 prefectural-level cities and 24 prefectures across Japan.

• Financial Position

  • Total cash and cash equivalents plus marketable securities reached 10.955 billion yen. Total interest-bearing debt is 11.458 billion yen, resulting in a net interest-bearing debt balance of 503 million yen, which decreased compared to the end of the prior fiscal year.
  • Net interest-bearing debt relative to EBITDA (which hit 1.145 billion yen this interim period) remains at a healthy, manageable level with no solvency concerns. Total net assets grew to approximately 15.2 billion yen.

• Dividend Policy

  • The company maintains its previously announced dividend policy: an annual dividend of 120 yen per share, with a payout ratio target of 35% or higher, in line with the mid-term management plan. The interim dividend is set at 60 yen per share, with the full-year expected dividend remaining unchanged.

1. Dispensing Pharmacy Business: Current period revenue is 13.056 billion yen, contributing 48.5% of total consolidated revenue. Prior period revenue was 11.911 billion yen, representing a 1.145 billion yen year-over-year increase. Current period operating profit is 658 million yen, up from 551 million yen in the prior period. As of the end of the 2nd quarter, the segment operates 98 stores, with 46 located in Mie Prefecture (the company's headquarters region) and 14 in the Kyoto area.
2. Healthcare Business: Current period revenue is 4.381 billion yen, contributing 16.3% of total consolidated revenue. Prior period revenue was 3.962 billion yen, representing a 419 million yen year-over-year increase. Current period operating profit is 14 million yen, down from 127 million yen in the prior period. The segment added two new care facilities in the first half: a 50-bed residential care facility opened in Kuwana City, Mie Prefecture in March, and the company acquired all shares of Sunrise Villa Tsuchiura, a 137-bed residential care facility operating in Ibaraki Prefecture, in August.
3. Pharmaceutical Wholesale Business: Current period revenue is 9.376 billion yen, contributing 34.8% of total consolidated revenue. Prior period revenue was 6.701 billion yen, representing a 2.675 billion yen year-over-year increase. Current period operating profit is 89 million yen, down from 194 million yen in the prior period. The segment added two new subsidiaries in the reporting period: Kochi Daiichi Pharmaceutical (based in Kochi Prefecture) acquired in May, and Site Pharmaceutical (based in Aichi Prefecture) acquired in July. The segment's branch/office network now totals 23 locations across Japan.

• The full-year fiscal 2026 net profit plan of 1.25 billion yen is maintained, with interim progress at 53.3% which management describes as on track.
• M&A activity will continue as a core growth strategy, with the company prioritizing deal opportunities in the pharmaceutical wholesale and healthcare/care segments, in line with the mid-term plan.
• The company's 35%+ payout ratio dividend policy is maintained as a core guideline for shareholder returns going forward.
• Geographic expansion will remain focused on the company's existing operating regions rather than greenfield expansion into entirely new areas, with no change to this long-standing strategy.

• Rising cost pressures: The pharmaceutical wholesale segment has seen rapid cost increases for two years, and this trend continues as of the reporting period, pressuring overall segment and group profitability.
• M&A-related costs: Unplanned deal fees and M&A integration costs for transactions in the healthcare and pharmaceutical wholesale segments reduced operating profit in the reporting period, and one-time costs may continue to impact near-term results as additional M&A is pursued.
• Profitability pressure from M&A-driven asset growth: ROA, ROE and ROIC all declined year-over-year due to M&A-driven expansion of total assets, and overall group profit margins declined due to the impact of rising pharmaceutical wholesale costs.
• Labor shortage risk: The healthcare (care) segment is not able to hire staff as quickly as planned to support expansion, creating operational headwinds for new facility openings.

Q: Will Medical Ichiko continue pursuing M&A in the generic pharmaceutical wholesale segment, given ongoing industry consolidation that has reduced available target options?

A: Management confirms the industry is in the final stage of consolidation, with far fewer available targets than in prior years. The company will continue to pursue expansion opportunities when attractive deals arise, aligned with its core growth strategy. Management declined to comment on specific ongoing discussions or existing prospective partners.

Q: What is the core focus for post-merger integration (PMI) for generic pharmaceutical wholesale M&A deals to deliver synergies faster?

A: Management states the top priority for PMI is maintaining operational continuity for the acquired business. The most critical factor to achieve this is building shared corporate culture between the acquirer and target, rather than only focusing on financial and operational number alignment.

Q: What is the company's approach to dividend policy going forward, and when would the company change or increase dividend payouts?

A: Management committed to the 35%+ payout ratio guideline set in this year's mid-term plan, with dividends increasing proportionally as pre-tax profit grows. Management notes that large concentrated investment outlays have historically been rare for the company, and the 35%+ payout ratio will remain the key benchmark for the foreseeable future.

Q: How does the company balance M&A growth with profitability, given recent near-term margin declines?

A: Management points out that interim revenue has grown roughly 50% year-over-year, while goodwill on the balance sheet has only increased slightly. The company prioritizes deals that require very limited goodwill outlays, which limits the negative impact of M&A on long-term earnings, and this disciplined approach is a core strength of the company's M&A strategy.